Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019)
Publication
, Journal Article
Moore, KN; Secord, AA; Geller, MA
Published in: LANCET ONCOLOGY
May 1, 2019
Duke Scholars
Published In
LANCET ONCOLOGY
EISSN
1474-5488
ISSN
1470-2045
Publication Date
May 1, 2019
Volume
20
Issue
5
Start / End Page
E242 / E242
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Moore, K. N., Secord, A. A., & Geller, M. A. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019). LANCET ONCOLOGY, 20(5), E242–E242.
Moore, K. N., A. A. Secord, and M. A. Geller. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019).” LANCET ONCOLOGY 20, no. 5 (May 1, 2019): E242–E242.
Moore KN, Secord AA, Geller MA. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019). LANCET ONCOLOGY. 2019 May 1;20(5):E242–E242.
Moore, K. N., et al. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019).” LANCET ONCOLOGY, vol. 20, no. 5, ELSEVIER SCIENCE INC, May 2019, pp. E242–E242.
Moore KN, Secord AA, Geller MA. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019). LANCET ONCOLOGY. ELSEVIER SCIENCE INC; 2019 May 1;20(5):E242–E242.
Published In
LANCET ONCOLOGY
EISSN
1474-5488
ISSN
1470-2045
Publication Date
May 1, 2019
Volume
20
Issue
5
Start / End Page
E242 / E242
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis